相关实验视频
Updated: Jan 14, 2026

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.3K
伊瓦布拉丁作为抗抗环素诱导心脏毒性的心脏保护剂:叙述性审查
Reza Golchin Vafa1, Mohammadali Ranjbar2
1Shiraz University of Medical Sciences, Zand street, Shiraz, Iran. Rezagolchinvafa@gmail.com.
Cardiovascular drugs and therapy
|October 23, 2025
概括
伊瓦布拉丁在预防由 antracycline 化疗引起的心脏损伤方面表现有前途. 需要进一步的试验,但它可能会改善癌症患者的治疗结果和生活质量.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
背景情况:
- 抗环素化疗可以引起心脏毒性,限制治疗选择,影响患者的生存.
- 一种降低心率的药物伊瓦布拉丁正在研究其心脏保护性质.
- 了解环素诱导心肌病 (AIC) 的机制对于开发有效的干预措施至关重要.
研究的目的:
- 审查和评估关于伊瓦布拉丁在预防或减少环素诱导心脏毒性的作用的证据.
- 分析机理学,临床前和临床数据,支持伊瓦布拉丁的心脏保护潜力.
- 评估艾瓦布拉丁在心脏瘤学中的转化价值.
主要方法:
- 在PubMed,Scopus和Web of Science的综合文献综述.
- 对艾瓦布拉丁对心脏功能和细胞机制的影响的实验和临床研究的分析.
- 评估与环素治疗和心脏毒性相关的数据.
主要成果:
- 临床前数据显示,伊瓦布拉丁可降低心肌细胞中的氧化应激,炎症和亡.
- 伊瓦布拉丁在临床前模型中保留了心肌功能和左心室喷射率.
- 临床发现表明,伊瓦布拉丁可以减轻心脏毒性,而不会影响化疗疗效或血压.
结论:
- 伊瓦布拉丁通过多种机制显示出显著的心脏保护潜力,可以通过多种机制对抗antracycline诱导的心脏毒性.
- 大规模的随机试验是必要的,以确认伊瓦布拉丁的疗效和安全性.
- 将伊瓦布拉丁纳入精密心脏瘤学可以改善接受 antracyclines 的癌症患者的治疗结果.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
645
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
645
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K

